IP Library Granted Patent US 10,106,615
Granted Patent B2
US 10,106,615 · App. 13/900,791 · Granted Oct 23, 2018

Nucleic acids encoding human monoclonal antibodies that bind CXCR4

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,615
App. No.
13/900,791
Granted
Oct 23, 2018
Kind
B2
Abstract

The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.

Claims (21)

1. An isolated nucleic acid encoding a monoclonal antibody, or an antigen-binding portion thereof, which specifically binds to human CXCR4, wherein the monoclonal antibody or antigen-binding portion thereof comprises:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 1;

(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 5;

(c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 9;

(d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 13;

(e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 17; and

(f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 21.

2. The nucleic acid of claim 1 , wherein the monoclonal antibody or antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 25; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 29.

3. The nucleic acid of claim 1 , wherein the monoclonal antibody or antigen-binding portion thereof is an IgG1, IgG2, IgG3 or IgG4 antibody or a portion thereof.

4. The nucleic acid of claim 1 , wherein the antigen-binding portion of the monoclonal antibody is a Fab, Fab′ or F(ab′) 2 , Fv, dAb, or scFv fragment.

5. The nucleic acid of claim 3 , wherein the monoclonal antibody or antigen-binding portion thereof is an IgG1 or IgG4 antibody or a portion thereof.

6. An expression vector comprising the nucleic acid of claim 1 .

7. An expression vector comprising the nucleic acid of claim 2 .

8. A host cell comprising the expression vector of claim 6 .

9. A host cell comprising the expression vector of claim 7 .

10. A method for preparing an anti-CXCR4 antibody or an antigen-binding portion thereof which comprises expressing the antibody or antigen-binding portion thereof in the host cell of claim 8 and isolating the antibody or antigen-binding portion thereof from the host cell.

11. A method for preparing an anti-CXCR4 antibody or an antigen-binding portion thereof which comprises expressing the antibody or antigen-binding portion thereof in the host cell of claim 9 and isolating the antibody or antigen-binding portion thereof from the host cell.

12. The nucleic acid of claim 1 , which is a cDNA.

13. The nucleic acid of claim 2 , which is a cDNA.

Assignments (2)
MERGER Recorded Mar 19, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035226/0690 →
MERGER Recorded Jun 13, 2013
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 030603/0924 →